BNP Paribas Financial Markets Has $2.13 Million Position in Repligen Co. (NASDAQ:RGEN)

BNP Paribas Financial Markets trimmed its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 75.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,298 shares of the biotechnology company's stock after selling 44,809 shares during the quarter. BNP Paribas Financial Markets' holdings in Repligen were worth $2,128,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tidal Investments LLC raised its stake in Repligen by 11.6% during the first quarter. Tidal Investments LLC now owns 1,421 shares of the biotechnology company's stock worth $261,000 after acquiring an additional 148 shares during the period. GAMMA Investing LLC increased its position in Repligen by 183.4% in the second quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company's stock worth $60,000 after buying an additional 310 shares during the period. Diversified Trust Co increased its position in Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after buying an additional 106 shares during the period. V Square Quantitative Management LLC lifted its stake in Repligen by 23.6% in the second quarter. V Square Quantitative Management LLC now owns 697 shares of the biotechnology company's stock valued at $88,000 after buying an additional 133 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Repligen by 937.8% during the second quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company's stock valued at $3,806,000 after acquiring an additional 27,280 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Price Performance

Shares of Repligen stock traded up $6.94 during trading on Friday, hitting $149.20. The stock had a trading volume of 590,853 shares, compared to its average volume of 693,035. The business has a fifty day moving average of $141.45 and a two-hundred day moving average of $141.99. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The firm has a market cap of $8.36 billion, a P/E ratio of -403.24, a PEG ratio of 4.48 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same period in the previous year, the business earned $0.23 earnings per share. Repligen's revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.